These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L. Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896 [Abstract] [Full Text] [Related]
6. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M. J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291 [Abstract] [Full Text] [Related]
8. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials. Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, Papavassilis C, Mpofu S. J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726 [Abstract] [Full Text] [Related]
9. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study. Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DC, Bao W, Dee CMA, Guana A, Tsai TF. J Dermatol; 2019 Sep; 46(9):752-758. PubMed ID: 31342560 [Abstract] [Full Text] [Related]
14. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, McBride D. J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2178-2184. PubMed ID: 29846965 [Abstract] [Full Text] [Related]
18. Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region. Alpalhão M, Duarte J, Diogo R, Vandemeulebroecke M, Ortmann CE, Kasparek T, Filipe P. BioDrugs; 2022 Nov; 36(6):781-789. PubMed ID: 36334236 [Abstract] [Full Text] [Related]
19. Secukinumab: a review in moderate to severe plaque psoriasis. Garnock-Jones KP. Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871 [Abstract] [Full Text] [Related]